The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders
Aim. To assess the influence of the therapy of arterial hypertension with azilsartan medoxomil on the renal function in overweight or obese patients with concomitant metabolic disorders. Materials and methods. An international multicenter observational nonintervention prospective study included 1...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2021-12-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/96476/70728 |
| _version_ | 1819278101761228800 |
|---|---|
| author | Vera A. Nevzorova Tatiana A. Petrichko Irina E. Chazova Juliya V. Zhernakova |
| author_facet | Vera A. Nevzorova Tatiana A. Petrichko Irina E. Chazova Juliya V. Zhernakova |
| author_sort | Vera A. Nevzorova |
| collection | DOAJ |
| description | Aim. To assess the influence of the therapy of arterial hypertension with azilsartan medoxomil on the renal function in overweight or obese patients with concomitant metabolic disorders.
Materials and methods. An international multicenter observational nonintervention prospective study included 1945 patients, taking azilsartan medoxomil in accordance with approved prescribing information. The observation period reached 6 months.
Results. In patients with an initial glomerular filtration rate (GFR)60 ml/min/1.73 m2 or 60 ml/min/1.73 m2 mean change in systolic blood pressure after 6 months of therapy reached -32.511.1 and -30.413.6 mmHg, correspondingly, while the change in diastolic blood pressure was -13.78.8 and -14.29.4 mmHg, respectively. No decrease in renal function was observed. Moreover, in patients with an initial GFR60 ml/min/1.73 m2 GFR increased significantly (p0.001).
Conclusion. Azilsartan medoxomil, prescribed as monotherapy or in free combinations, provided an effective control of blood pressure in patients with arterial hypertension with both normal or moderately reduced and initially significantly reduced renal function. High efficacy and acceptability of the drug was associated with a beneficial effect on renal function, which allows to consider azilsartan medoxomil as the drug of choice for the treatment of hypertension in patients with concomitant metabolic disorders. |
| first_indexed | 2024-12-24T00:06:40Z |
| format | Article |
| id | doaj.art-36dec9a9b76f463fa044ebb087537133 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-24T00:06:40Z |
| publishDate | 2021-12-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-36dec9a9b76f463fa044ebb0875371332022-12-21T17:24:59Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422021-12-0193121510151510.26442/00403660.2021.12.20127078007The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disordersVera A. Nevzorova0https://orcid.org/0000-0002-0117-0349Tatiana A. Petrichko1https://orcid.org/0000-0003-1770-3370Irina E. Chazova2https://orcid.org/0000-0002-9822-4357Juliya V. Zhernakova3https://orcid.org/0000-0001-7895-9068Pacific State Medical UniversityPostgraduate Institute for Public Health WorkersNational Medical Research Center of CardiologyNational Medical Research Center of CardiologyAim. To assess the influence of the therapy of arterial hypertension with azilsartan medoxomil on the renal function in overweight or obese patients with concomitant metabolic disorders. Materials and methods. An international multicenter observational nonintervention prospective study included 1945 patients, taking azilsartan medoxomil in accordance with approved prescribing information. The observation period reached 6 months. Results. In patients with an initial glomerular filtration rate (GFR)60 ml/min/1.73 m2 or 60 ml/min/1.73 m2 mean change in systolic blood pressure after 6 months of therapy reached -32.511.1 and -30.413.6 mmHg, correspondingly, while the change in diastolic blood pressure was -13.78.8 and -14.29.4 mmHg, respectively. No decrease in renal function was observed. Moreover, in patients with an initial GFR60 ml/min/1.73 m2 GFR increased significantly (p0.001). Conclusion. Azilsartan medoxomil, prescribed as monotherapy or in free combinations, provided an effective control of blood pressure in patients with arterial hypertension with both normal or moderately reduced and initially significantly reduced renal function. High efficacy and acceptability of the drug was associated with a beneficial effect on renal function, which allows to consider azilsartan medoxomil as the drug of choice for the treatment of hypertension in patients with concomitant metabolic disorders.https://ter-arkhiv.ru/0040-3660/article/viewFile/96476/70728arterial hypertensionoverweightobesityrenal functionazilsartan medoxomilnonintervention study |
| spellingShingle | Vera A. Nevzorova Tatiana A. Petrichko Irina E. Chazova Juliya V. Zhernakova The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders Терапевтический архив arterial hypertension overweight obesity renal function azilsartan medoxomil nonintervention study |
| title | The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders |
| title_full | The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders |
| title_fullStr | The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders |
| title_full_unstemmed | The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders |
| title_short | The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders |
| title_sort | assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders |
| topic | arterial hypertension overweight obesity renal function azilsartan medoxomil nonintervention study |
| url | https://ter-arkhiv.ru/0040-3660/article/viewFile/96476/70728 |
| work_keys_str_mv | AT veraanevzorova theassessmentofrenalfunctionduringthetherapyofarterialhypertensionwithazilsartanmedoxomilinpatientswithobesityoroverweightandconcomitantmetabolicdisorders AT tatianaapetrichko theassessmentofrenalfunctionduringthetherapyofarterialhypertensionwithazilsartanmedoxomilinpatientswithobesityoroverweightandconcomitantmetabolicdisorders AT irinaechazova theassessmentofrenalfunctionduringthetherapyofarterialhypertensionwithazilsartanmedoxomilinpatientswithobesityoroverweightandconcomitantmetabolicdisorders AT juliyavzhernakova theassessmentofrenalfunctionduringthetherapyofarterialhypertensionwithazilsartanmedoxomilinpatientswithobesityoroverweightandconcomitantmetabolicdisorders AT veraanevzorova assessmentofrenalfunctionduringthetherapyofarterialhypertensionwithazilsartanmedoxomilinpatientswithobesityoroverweightandconcomitantmetabolicdisorders AT tatianaapetrichko assessmentofrenalfunctionduringthetherapyofarterialhypertensionwithazilsartanmedoxomilinpatientswithobesityoroverweightandconcomitantmetabolicdisorders AT irinaechazova assessmentofrenalfunctionduringthetherapyofarterialhypertensionwithazilsartanmedoxomilinpatientswithobesityoroverweightandconcomitantmetabolicdisorders AT juliyavzhernakova assessmentofrenalfunctionduringthetherapyofarterialhypertensionwithazilsartanmedoxomilinpatientswithobesityoroverweightandconcomitantmetabolicdisorders |